VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Anti-CD19-chimeric-antigen-receptor-transduced T cells
Phase 1
Biologic
N
National Cancer Institute (NCI)
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
B-Cell
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
B-Cell
Phase 1
Completed
Clinical
Trials by Indication
[1]
B-Cell
1 trial
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
Completed
·
N
National Cancer Institute (NCI)
·
Phase 1
·
NCT01087294
·
85 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Anti-CD19-chimeric-antigen-receptor-transduced T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Anti-CD19-chimeric-antigen-receptor-transduced T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Anti-CD19-chimeric-antigen-receptor-transduced T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Phase 1
[1]
Company
N
National Cancer Institute (NCI)
Related News